On the other hand, the principal pharmacological action of tacrolimus in AD is to suppress T-cell activation by inhibiting IL-4 and IL-5 production, which in turn reduces IgE production in B cells and mast cells degranulation. Here, IGHE is linked to Alzheimer disease.